Please use this identifier to cite or link to this item:
https://essuir.sumdu.edu.ua/handle/123456789/91877
Or use following links to share this resource in social networks:
Tweet
Recommend this item
Title | Efficacy of polyacrylamide hydrogel for female urinary incontinence: outcome of a single centre |
Authors |
Buckingham, M.
Sultana, M. Thomas, J.M. Andrews, V. |
ORCID | |
Keywords |
polyacrylamide hydrogels urinary incontinence urinary stress incontinence |
Type | Article |
Date of Issue | 2023 |
URI | https://essuir.sumdu.edu.ua/handle/123456789/91877 |
Publisher | Sumy State University |
License | Creative Commons Attribution 4.0 International License |
Citation | Buckingham M, Sultana M, Thomas JM, Andrews V. Efficacy of polyacrylamide hydrogel for female urinary incontinence: outcome of a single centre. East Ukr Med J.1502023;11(2):149-154. DOI: https://doi.org/10.21272/eumj.2023;11(2):149-154 |
Abstract |
Introduction: Periurethral injection with polyacrylamide hydrogel (PAHG, Bulkamid®) is a minimally invasive treatment option to be considered for women with stress urinary incontinence. The manufacturer recommends injecting between 1.5 ml and 2 ml periurethrally. This study aims to evaluate the long-term efficacy of PAHG, and to determine whether there is a correlation between the volume of PAHG injected and the outcome in terms of symptoms.
Methods: A retrospective study was conducted between 2011 and 2018. Patients were contacted by telephone and the International Consultation on Incontinence Questionnaire – Urinary Incontinence Short Form (ICIQ-UI SF) was used to assess their symptoms. A linear regression analysis test was performed to assess the correlation between the outcome and the volume of PAHG injected.
Results: One hundred and fifteen PAHG injections were performed on 101 patients. The volume of PAHG injected ranged from 0.8 ml to 3 ml. Two patients reported procedure-related complications. Of the patients that attended their three-month follow-up, 62 (58.5%) patient-episodes reported an improvement. 62 patients were contacted by telephone and the median length of follow-up was 37.5 months. An improvement in the ICIQ-UI SF score was observed in 45.8% of patients with a mean improvement of 4 points. The volume of PAHG injected did not affect the outcome. 31% also reported a benefit with PAHG five years after their injection following previous incontinence surgery.
Conclusions: PAHG injection is safe and improves symptoms of urinary incontinence at up to 7.5 years in 45.8% of women. PAHG is also useful after previous incontinence surgery. The volume of PAHG injected did not influence the outcome. |
Appears in Collections: |
Східноукраїнський медичний журнал |
Views
Canada
1
Egypt
1
Germany
1
Hong Kong SAR China
1
Ireland
6
Mongolia
1
Pakistan
914
Poland
1
South Korea
243
Ukraine
1
United Kingdom
121
United States
7242
Unknown Country
60
Downloads
Albania
1
Germany
1
India
1
Italy
3177
Japan
1
Poland
1
Singapore
1
South Korea
1
Turkey
1
Ukraine
3175
United Kingdom
3175
United States
8594
Files
File | Size | Format | Downloads |
---|---|---|---|
Buckingham_urinary_incontinence.pdf | 767.38 kB | Adobe PDF | 18129 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.